# US 2026/0083705 A1 · Transdermal dexmedetomidine for treating agitation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083705 A1
- Document ID: US20260083705A1
- Status: Published application
- Kind: A1
- Application number: 19/338,730
- Filed: 2025-09-24
- Published: 2026-03-26
- Earliest claimed: 2024-09-24
- Assignees: Teikoku Pharma USA, Inc.
- Applicants: Teikoku Pharma USA, Inc.
- Inventors: Wan-Ning Song; Gary G. Kay
- Web page: https://patentgrep.com/patent/US20260083705A1

## CPC

- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/7038: {Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}
- A61K 9/7061: {Polyacrylates}
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of using transdermal delivery patches containing dexmedetomidine to treat agitation.

## Claims

### Claim 1

A method of treating agitation in a subject in need thereof, comprising applying one or more transdermal delivery patches to a skin surface of the subject, who is not agitated at the time of application, wherein:
each transdermal delivery patch comprises a pharmaceutical composition comprising dexmedetomidine;
the one or more transdermal delivery patches deliver a therapeutically effective non-sedating amount of dexmedetomidine to the subject;
each transdermal delivery patch comprises a drug layer affixed to a backing layer, wherein the drug layer comprises from 1 mg to 3.5 mg dexmedetomidine, a pressure sensitive adhesive comprising a hydroxyl functionalized acrylate polymer, and lauryl lactate; wherein:
the drug layer has an adhesive surface suitable for adhesion to a skin surface, wherein the adhesive surface has a surface area from 3 cm2 to 20 cm2; and
the backing layer comprises polyethylene and polyethylene terephthalate;
the subject has an Agitated Behavior Scale (ABS) score of at least 22 at least once when assessed on one of the four days prior to application of the one or more transdermal delivery patches; and
the subject's ABS score 96 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject is reduced compared to the subject's baseline ABS score assessed prior to application of the one or more transdermal delivery patches.

### Claim at position 2

2-81. (canceled)

### Claim 82 (depends on 1)

The method of claim 1, wherein the agitation is associated with dementia of the Alzheimer's type.

### Claim 83 (depends on 1)

The method of claim 1, wherein the subject has a diagnosis of dementia of probable Alzheimer's Disease.

### Claim 84 (depends on 1)

The method of claim 1, wherein the subject has a Mini-Mental State Exam (MMSE) score of ≤23 when administered on one of the 7 days prior to applying the one or more transdermal patches.

### Claim 85 (depends on 1)

The method of claim 1, wherein the subject's ABS score 168 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject for 4 days is reduced compared to the subject's baseline ABS score assessed prior to application of the one or more transdermal delivery patches.

### Claim 86 (depends on 1)

The method of claim 1, wherein the subject's Cohen Mansfeld Agitation Inventory (CMAI) total score 15 days after application of the one or more transdermal delivery patches to the skin surface of the subject for 4 days is reduced compared to the subject's baseline CMAI total score.

### Claim 87 (depends on 1)

The method of claim 1, wherein the subject's Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) score 168 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject for 4 days is reduced compared to the subject's baseline NPI-NH score.

### Claim 88 (depends on 1)

The method of claim 1, wherein subject's Episodic Agitation Scale-Nursing Home (EAS-NH) score 24 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject for 4 days is reduced compared to the subject's baseline EAS-NH score assessed prior to application of the one or more transdermal delivery patches.

### Claim 89 (depends on 1)

The method of claim 1, wherein the subject's Clinical Global Impression Scale-Change (CGI-C) score 96 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject for 4 days is reduced compared to the subject's baseline CGI-C score measured prior to application of the one or more transdermal delivery patches.

### Claim 90 (depends on 1)

The method of claim 1, wherein the subject's Clinical Global Impression Scale-Severity (CGI-S) score 96 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject for 4 days is reduced compared to the subject's baseline CGI-S-score measured prior to application of the one or more transdermal delivery patches.

### Claim 91 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches each comprise from 1 mg to 2 mg dexmedetomidine.

### Claim 92 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches each comprise 1.46 mg dexmedetomidine.

### Claim 93 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches each comprise from 2.5 mg to 3.5 mg dexmedetomidine.

### Claim 94 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches each comprise 2.92 mg dexmedetomidine.

### Claim 95 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches collectively comprise from 2.5 mg to 3.5 mg dexmedetomidine.

### Claim 96 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches collectively comprise 2.92 mg dexmedetomidine.

### Claim 97 (depends on 1)

The method of claim 1, wherein the adhesive surface has a surface area from 6 cm2 to 7 cm2.

### Claim 98 (depends on 97)

The method of claim 97, wherein the adhesive surface has a surface area of 6 cm2.

### Claim 99 (depends on 1)

The method of claim 1, wherein the adhesive surface has a surface area from 12 cm2 to 13 cm2.

### Claim 100 (depends on 99)

The method of claim 99, wherein the adhesive surface has a surface area of 12 cm2.

### Claim 101 (depends on 1)

The method of claim 1, wherein the transdermal delivery device further comprises a release liner adhered to the adhesive surface of the drug layer.

### Claim 102 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches provide an in vitro average flux, when measured on human cadaver skin, from 0.005 μg/cm2/hr to 5 μg/cm2/hr 24 hours after application of the one or more transdermal delivery patches to a skin surface and maintenance of contact between the skin surface and the one or more transdermal delivery patches.

### Claim 103 (depends on 1)

The method of claim 1, wherein the one or more transdermal delivery patches provide an in vitro dexmedetomidine peak flux, when measured on human cadaver skin, from 0.1 μg/cm2/hr to 3 μg/cm2/hr.

### Claim 104 (depends on 1)

The method of claim 1, wherein:
the agitation is associated with dementia of the Alzheimer's type;
the one or more transdermal delivery patches each comprise from 1 mg to 2 mg dexmedetomidine; and
the adhesive surface has a surface area from 6 cm2 to 7 cm2.

### Claim 105 (depends on 104)

The method of claim 104, wherein the one or more transdermal delivery patches each comprise 1.46 mg dexmedetomidine.

### Claim 106 (depends on 105)

The method of claim 105, wherein the surface area is 6 cm2.

### Claim 107 (depends on 1)

The method of claim 1, wherein:
the agitation is associated with dementia of the Alzheimer's type;
the one or more transdermal delivery patches each comprise from 2.5 mg to 3.5 mg dexmedetomidine; and
the adhesive surface has a surface area from 12 cm2 to 13 cm2.

### Claim 108 (depends on 107)

The method of claim 107, wherein the one or more transdermal delivery patches each comprise 2.92 mg dexmedetomidine.

### Claim 109 (depends on 108)

The method of claim 108, wherein the surface area is 12 cm2.

### Claim 110

A method of treating agitation in a subject in need thereof, comprising applying one or more transdermal delivery patches to a skin surface of the subject, who is not agitated at the time of application, wherein:
each transdermal delivery patch comprises a pharmaceutical composition comprising dexmedetomidine;
the one or more transdermal delivery patches deliver a therapeutically effective non-sedating amount of dexmedetomidine to the subject;
each transdermal delivery patch comprises a drug layer affixed to a backing layer, wherein the drug layer comprises from 1 mg to 3.5 mg dexmedetomidine, a pressure sensitive adhesive comprising a hydroxyl functionalized acrylate polymer, and lauryl lactate; wherein:
the drug layer has an adhesive surface suitable for adhesion to a skin surface, wherein the adhesive surface has a surface area from 3 cm2 to 20 cm2; and
the backing layer comprises polyethylene and polyethylene terephthalate;
the subject has a diagnosis of dementia of probable Alzheimer's Disease; and
the subject's ABS score 96 hours following application and maintenance of the one or more transdermal delivery patches on the skin surface of the subject is reduced compared to the subject's baseline ABS score assessed prior to application of the one or more transdermal delivery patches.
